International Poster Session3 (JDDW)
October 28, 9:30–10:10, Room 15 (Marine Messe Fukuoka Arena Digital Poster Session)
IP-14_G

Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: A clinicopathological study of 16 cases

Yoshifumi Hori1
Co-authors: Hidetaka Yamamoto2, Shinichiro Kawatoko2,3, Takahide Tanaka3, Yuichi Matsuno3, Koji Kato4, Yuhki Koga5, Hiroaki Miyoshi6, Koichi Ohshima6, Shotaro Nakamura7, Takehiro Torisu3
1
Onga Nakama Medical Association Onga Hospital
2
Department of Anatomic Pathology, Kyushu University Graduate School of Medicine Sciences
3
Department of Medicine and Clinical Science, Kyushu University Graduate School of Medicine Sciences
4
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine Sciences
5
Department of Pediatrics, Kyushu University Graduate School of Medicine Sciences
6
Department of Pathology, Kurume University School of Medicine
7
Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University
Lymphoproliferative disorder (LPD) and myeloid neoplasm can occur in patients with inflammatory bowel disease (IBD). However, the frequency and clinicopathological features of IBD-associated lymphoid and myeloid proliferative disorder (LMPD) in Japanese patients is still unclear. In this study, we analyzed a total of 16 cases of IBD-LMPD for clinicopathological and histological features. Based on the status of using immunosuppressants such as biologics and immunomodulators, EBV infection, and histopathology, the 16 cases were classified into the Group I (high-grade LPD; n=7), Group II (low-grade LPD; n=6), and Group III (myeloid neoplasms; n=3). Most patients in Group I were undergoing strong immunosuppressive therapy, and the LPD lesions corresponded to high-grade B-cell or T/NK-cell lymphoma often with EBV infection, and that prognosis were worse.
Page Top